Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Assay of TMPRSS2:ERG and PCA in Canary PASS

Assay of TMPRSS2:ERG and PCA in Canary PASS

368

No involved investigator sites defined.

Urinary PCA3 and TMPRSS2:ERG
Proteomics
Prostate and Urologic Cancers Research Group
2

The identification of biomarkers that, at the time of diagnosis, associate with the presence of, or progression to, aggressive prostate cancer will transform the clinical management of this malignancy. If patients and their physicians have reliable and valid tools for estimating the risk of disease-specific morbidity, then more patients might opt for and adhere to active surveillance regimens, and consequently reduce overtreatment and the attendant substantial costs and harms. Also, a marker or marker panel with high accuracy for progression on active surveillance will identify those men who could be placed on less intensive surveillance protocols with fewer repeated prostate biopsies, reducing the risks and costs of invasive procedures. The study presented here is a step toward validating such biomarkers.

1.   Assess the frequency of TMPRSS2:ERG gene-fusion in whole urines of an active surveillance population. 2.   Evaluate urinary TMPRSS2:ERG and PCA3 levels and assess if there is a correlation with progression. 3.   Evaluate longitudinal changes in urinary TMPRSS2:ERG and PCA3 levels and assess if there is a correlation with progression.
Gen-Probes TMA assay

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html